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Abstract
The overall vision of the modern science needs to change to a revalorization of the natu-
ral compounds and their beneficial effects on human diseases, such as cancer. Medicinal 
mushrooms have been used since thousands of years due to its healing properties. 
Maitake (Grifola frondosa) is presented as one of the most interesting medicinal mushrooms 
that have been studied. Until now, Maitake D-Fraction may have anticarcinogenic activ-
ity, preventing oncogenesis and metastasis in certain tumor types. However, the exact 
molecular mechanism by which D-Fraction acts are yet unknown. The results shown in 
this chapter suggest that Maitake D-Fraction Pro4X, administered intraperitoneally, pre-
vents significantly the development of mammary tumorigenesis, increases survival, and 
reduces the process of angiogenesis in BALBc mice. Although yet to determine the active 
component of the extract and the molecular mechanism by which it operates in the breast 
carcinogenesis process. The socioeconomic impact of this research project could be impor-
tant, considering that in Argentina similar studies using natural compounds derived from 
medicinal mushrooms for cancer therapy have not yet been performed. The beneficial 
effects of Maitake, if proven, could be useful for the treatment of cancer patients who 
are undergoing chemotherapy or radiation or for breast cancer prevention in high-risk 
population.
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1. Introduction
Breast cancer now represents the second most common type of tumor pathology in the world 
and the highest incidence representing the leading cause of death in women in the world [1]. 
During cancer treatment, tumors often develop resistance mechanisms to  chemotherapeutics, 
which occur in about 30% of patients treated with antineoplastic agents. For this reason, and 
for the many adverse effects of chemotherapy, more effective and less invasive therapeutic 
alternatives are sought. In the past century, with the development experienced in the chem-
ical-pharmaceutical area, there was an increase in the production of synthetic and semisyn-
thetic chemical drugs. This led to an increase in adverse reactions and negative side effects, in 
addition to the high cost of acquisition of these compounds. Therefore, there is a widespread 
tendency to use products derived from natural sources such as plants and edible mushrooms, 
consumed as dietary supplements in an increasing number of countries in the recent decades 
[2, 3]. These substances, which exhibit pharmacological properties in a broad spectrum of 
diseases, have shown their safety compared to drugs with chemical synthetic origin [4, 5].
An approach to the “ideal” anticancer drug could be derived from selective natural agents 
with low toxicity, such as fungal and extracts of medicinal plants, which possess significant 
antitumor and anticarcinogenic activities and avoid toxic side effects. Today, there is great 
interest in the study of natural extracts that meet these characteristics [6]. Plants and medici-
nal mushrooms are a source of obtaining active ingredients of marked importance in current 
research. Nature is a rich source of drugs. It is believed, for example, that only about 10% 
of the estimated 140,000 species of fungi on Earth are known. It is also estimated that only 
5% of these species have been known to have pharmacological properties. The international 
scientific community has focused its efforts on the search for new sources of active ingredi-
ents from plants and fungi as potential anticancer drug [7, 8]. From natural products with 
anticancer activity, the best known are the vinca alkaloids (vincristine and vinblastine) iso-
lated from the Madagascar periwinkle, Catharanthus roseus, C. roseus [9]. Probably the most 
important discovery and development is Paclitaxel (taxol) obtained from Taxus brevifolia tree 
[10, 11]. The new era of anticancer drug has been led by products such as taxol and docetaxol, 
among others. The discovery of penicillin from Filamentous fungus, Penicillium notatum and 
its therapeutic use, in the 1940s, became a new era of medicine and the “Golden Age” of 
antibiotics and thus promoted intense research in the nature as a source of new bioactive 
agents. Plants have a long history in the treatment of cancer, although they have often been 
observed with some skepticism by the own characteristics of the disease; but now, many 
people with cancer want to undergo known therapies as alternative products mainly from 
traditional usage, for example homeopathy and diet, among others, are widely used in ori-
ental medicine. The traditional oriental medicine have been used for thousands of years as a 
medicinal mushrooms such as Grifola frondosa (Maitake) [12], Ganoderma lucidum (Reishi), 
Inonotus obliquus (Chaga), Lentinus edodes (Shiitake), among others. The production of bio-
logically active fungal metabolites is a very broad field and is a promising study, which until 
now has been poorly studied [13–15]. Modulation of the immune system through stimulation 
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or suppression of it can contribute to maintaining good health. Numerous immune system 
stimulating substances have been isolated from higher plants and fungi, and open doors for 
the development of novel drugs. They are looming, thus, as an effective alternative for the 
treatment of various health conditions that alter the normal balance of the body’s immune 
response. The use of mushrooms that activate host defense mechanisms ( immunostimulatory 
or  immunopotentiating) provides an additional  therapeutic tool to conventional chemother-
apy. Given the limitations of  conventional therapies to reduce cancer mortality rate, many 
efforts are focused on cancer prevention. Within this context, the use of immunopotentiating 
and inmunostimulating agents as well as biological response modifiers (BRM), capable of 
stimulating the immune cells that can identify tumor cells as foreign, eliminate, and prevent 
carcinogenesis, have gained prominence [16–18]. An immunomodulatory polysaccharide 
obtained from higher fungi is the grifolano (GRN), derived from Grifola frondosa. Several 
studies suggest that the mechanism of the antitumor activity of GRN is strongly related to 
immunomodulation [19]. It has been shown that the active grifolano in vitro macrophages 
to produce the tumor necrosis factor-alpha (TNF-α) [20]. The β-glucans are one of the most 
abundant forms of polysaccharides found in the cell wall of bacteria and fungi, which exert 
effects on the immune system by stimulating phagocytic activity, activating leukocytes, and 
inducing the production of various cytokines, which could give them their antitumor activity. 
It has been shown that oral administration of β-glucans extracts derived from Grifola frondosa 
medicinal mushroom (Maitake) could stimulate hematopoiesis and recovery post-treatment 
with Paclitaxel in cancer patients [21]. Particularly β-glucans act on a variety of receptors 
related to immune system, particularly acting on Dectin-1 and CR3 receptors, which trigger 
a broad spectrum of immune responses [22]. The β-glucans targeting immune cells are mac-
rophages, neutrophils, monocytes, NK cells, and dendrites cells. Immunomodulatory func-
tions induced by β-glucans involve an innate and adaptive immune response. Maitake is an 
edible and a medicinal mushroom, whose extracts possess β-glucans with different degrees 
of purification and have antitumor properties [23]. The β-glucans are BRM that, unlike con-
ventional chemotherapeutics, activate or reinforce the host immune system, helping to elimi-
nate or inhibit tumor growth. It has been shown that fractions obtained from Maitake can 
fight cancer by slowing or stopping tumor growth; and preventing tumor metastasis [23]. On 
the other hand, could decrease the side effects of chemotherapy such as hair loss, pain, and 
nausea, and enhance its positive effects [23]. The immunomodulatory functions induced by 
β-glucans involve an innate response and adaptive immune response. However, the exact 
mechanisms of immune system activation mediated by β-glucans are still unknown and 
must be defined.
In this chapter, we present a summary of some experiments done in biomodels of mammary 
carcinogenesis. So far, we have demonstrated that the treatment with Maitake D-Fraction 
Pro4X prevents the development of mammary tumorigenesis, blocks tumor invasiveness, 
reduce tumor angiogenesis, increases overall survival in animals, and exhibits selective cyto-
toxicity [24–26]. Moreover, we also demonstrated that the use of Maitake D-Fraction Pro4X is 
safe and nontoxic as well.
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2. Direct effect of Maitake D-Fraction compared with Chemotherapy on 
breast tumour death
2.1. Effect of Maitake vs. chemotherapy on breast tumor death
In order to demonstrate if Maitake D-Fraction is able to kill breast cancer cells in culture, 
we measured the number of murine breast tumor LM3 cells death after treatment. The effects 
of increasing concentrations of β-glucans contained in Maitake D-Fraction Pro4X (0.036, 0.091, 
0.183, 0.367, and 0.734uM) on cell death were evaluated at 24, 48, and 72 hours of treatment. In 
parallel, we treated LM3 cells during the same time with chemotherapy drugs using a combina-
tion of doxorubicin and cyclophosphamide at increased concentrations from 5 to 40 μM and 
from 0.5 to 2.5 μM for each drug, respectively. Cell death was determined at 24, 48 and 72 hours 
of treatment according to the trypan blue exclusion stained method. Figure 1 shows the cell 
death values depending on the concentration of the used chemotherapeutic drugs (doxorubicin 
and cyclophosphamide) for 24, 48, and 72 hours after treatment. In all treatments, cell death was 
significantly higher (Student’s t-test, p ≤ 0.05) relative to untreated controls. It is also observed 
that the highest percentage of cell death (96.70%) corresponded to the higher concentration of 
chemotherapy used drugs (40 mM doxorubicin + 2.5 mM cyclophosphamide). The optimal time 
of the maximal cytolysis was the longest treatment at 72 hours. Cell death values depending on 
the concentration of Maitake Pro4X Fraction D at 24, 48, and 72 hours of treatment, as shown in 
Figure 2. The percentage of cell death increased depending on both, concentration of Maitake 
Pro4X used and time of treatment. The highest percentage of cell death (61.52%) corresponded 
to treatment with the highest dose of Maitake (0.734 μM) for 72 hours, the longest treatment.
Figure 1. Cell death caused by different concentrations of doxorubicin + cyclophosphamide at 24, 48, and 72 hours of 
treatment. The values represented the mean ± correspond to SD(N = 2). *p < 0.05 vs. control.
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In this work, we observed that both treatments, Maitake or chemotherapy, increased tumor 
cell death depending on the concentration and time of treatment. These results suggest that 
Maitake D-Fraction may have a chemotherapeutic effect by inducing a dose-dependent 
cell death. Here, we observed that the treatment with chemotherapeutic drugs increased 
mouse tumor cell death in a higher level compared to treatment with Maitake D-Fraction.
2.1.1. In vitro effect of Maitake on human breast tumour MCF-7 death cells
By another side, we performed the same experiments measuring the death in tumor human 
mammary cells (MCF-7). Using the time lapse microscope that takes pictures of the treated 
MCF-7 cell culture every 10 minutes during 1, 5, 10, and 24 hours (Figure 3A), it was found 
that Maitake D-Fraction increase the number of cell deaths significantly in a dose-dependent 
form, reaching the maximum deaths at the concentration of 367 μg/ml (equivalent to 0.367 μM) 
(Figure 3B). The treatment of tumoral MCF-7 breast cells at 24 hours with D-Fraction signifi-
cantly increase (p < 0.05) the percentage of cell death in comparison with untreated controls.
Figure 2. Cell death caused by different concentrations of Maitakeat 24, 48, and 72 hours of 
treatment. The values represented the mean ± correspond to SD (n = 2). *p < 0.05 vs. control.
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2.1.2. Maitake D-fraction decreased MCF7 cell viability and increased apoptosis
These results made us to think about whether Maitake D-Fraction really exerted anticancer 
effects and induces cell death directly or is toxic for those cells and able to kill any kind of cell. 
To probe this, we measure the effect of this compound in MCF7 cells viability and examine if 
the cell death trigger mechanisms are related to apoptosis. The cell deaths were measured by 
examining using the MTS assay in MCF7 cell cultures incubated with five different concen-
trations of D-Fraction. A gradual decrease in the number of viable cells was observed with 
Figure 3. Analysis of cell death induced by Maitake in MCF-7 cells employing the time-lapse microscope. MCF-7 cells 
at 70% of confluence were treated with and without (control) increased concentrations of Maitake D-Fraction. The 
experiments were performed by triplicate. Cells were placed in the time-lapse microscope under CO
2
 atmosphere, at 
room temperature during 24 hours. The camera was set up to take pictures every 10 minutes, using the 20× objective. 
Images and videos were analyzed employing specific software. (A) The representative image corresponding to the cell 
culture at 1, 5, 10, and 24 hours after Maitake treatment in the conditions indicated in the figure. (B) Corresponding to 
the approximate percentage of dead cells observed in each movie after 24 hours of Maitake incubation.
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increasing concentrations of D-Fraction (Figure 4A). In fact, we observed that the highest con-
centration of D-Fraction resulted in a significant decrease in cell viability in comparison to 
control untreated (Figure 4A) (*p < 0.05 vs. control). To evaluate whether this decrease in cell 
viability was due to apoptosis, we employed the TUNEL assay. MCF7 (4 × 104) cells were incu-
bated with increased concentrations of Maitake D-Fraction during 24 hours and the percentage 
of apoptotic cells was quantified. We observed that the treatment with this fraction, at any con-
centration, led to a significant increase in the number of apoptotic cells, in a dose-dependent 
manner (Figure 4B). Interestingly, nearly 95% of the cells became apoptotic whenever treated 
Figure 4. MCF-7 cell viability was evaluated after incubation with five concentrations of Maitake D-Fraction. (A) Cell 
viability was assessed by MTS assay. The results are expressed in absorbance values at 540 nm and are fold-increase 
relative to control cell cultures. Three independent experiments were performed in triplicate with identical results. *p 
= 0.05 vs. control (n = 9). (B) Apoptosis was increased at every incubation as evaluated by TUNEL assay, reaching 
statistical significance for every concentration of D-Fraction (*p < 0.05 vs. controls; **p < 0.01 vs. control). Bars represent 
the percentage of apoptotic cells evaluated by the ratio between TUNEL-stained cells and DAPI-stained nuclei in every 
culture. Experiments were repeated three times with identical results (n = 9). (C) Immunofluorescence for apoptotic cells 
(green). Note the increased number of apoptotic cells in 367 μg/ml Maitake-treated cells (Maitake) in comparison to 
untreated cells (control). Representative images are shown. Magnification ×200.
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with the highest concentration of Maitake D-Fraction (0.367 μM or 367 μg/ml) (Figure 4B). A 
representative microscope image of these findings is illustrated in Figure 4C. As observed, 
treatment with Maitake D-Fraction led to an effective increase in the number of apoptotic cells 
(green) as compared to the untreated culture. These findings indicated that Maitake D-Fraction 
was able to effectively induce apoptosis in human MCF-7 breast cancer cells.
2.2. Effect of Maitake D-Fraction on death of normal human breast cells MCF-10F
To investigate if Maitake D-Fraction is selective to cell death and only induces death on tumor 
cells not in normal cells, we performed studies using normal human breast cells MCF-10F. 
We operate at different times and increase concentrations of Maitake D-Fraction using an 
in vitro MCF-10F cell culture and measure cell death after treatment. Cells were incubated 
by  triplicate with D-Fraction at 37°C in controlled atmosphere with 5% CO
2
 in a serum-free 
medium. At the end of the treatment, cell deaths were determined by the technique of try-
pan blue exclusion assay, counting the percentage of dead and the percentage of live cells in 
Neubauer chamber. The assay were tested at increased concentrations of Maitake D-Fraction 
at 91, 183, and 367 μg/ml of culture medium during 24, 48, and 72 hours. All the experiments 
were performed by triplicate. Surprisingly, treatment of cells, normal mammary MCF-10F 
cells, with increased concentrations of D-Fraction did not cause significant increases in the 
percentage of cell death compared to control at the highest dose of 367 μg/ml equivalent to 
0.367 μM at any time assayed (Figure 5). In conclusion from these experiments, we confirm 
that Maitake D-Fraction only induced in vitro cell death by apoptosis in breast tumor cells 
without affecting normal breast cells at any concentrations or time of treatment.
Figure 5. Cell death caused by different concentrations of Maitake D-Fraction on MCF-10F cells at 24, 48, and 72 hours of 
treatment. The values represented the mean ± correspond to SD (n = 3). *p < 0.05 vs. control.
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3. Breast cancer prevention studies
3.1. Studies of breast tumor prevention by Maitake Pro4X in BALBc mice
3.1.1. Effect of Maitake D-Fraction Pro4X on breast cancer prevention
In order to demonstrate whether the purified extract Maitake D-Fraction Pro4X (from 
Mushroom Wisdom Inc, NJ, USA) was related to breast cancer prevention or inhibited the 
mammary tumorigenesis process, three independent experiments were performed employ-
ing 20 female nulliparous BALBc mice. Two groups were separated with 10 animals each, 
control group and Maitake D-Fraction group (5 mg/Kg) that were treated daily during 
15 days by intraperitoneal injection. After that, mammary tumorigenesis was induced using 
implant of 2 × 105 LM3 cells intraperitoneally. All animals were checked weekly for breast 
tumor development. Figure 6 shows the picture of mice abdominal area (peritoneal mam-
mary glands) from each condition after 30 days of tumor challenge. From this experiment, we 
observed that 100% of breast tumorigenesis was developed (10 out 10 animals) in the control 
group. However, only 3 out 10 animals (30% of tumorigenesis) developed mammary tumors 
in the condition treated with Maitake D-Fraction Pro4X (Pro4X) (Figure 6). The average from 
all the three independent experiments performed for prevention against breast tumorigenesis 
development in animals from the control group was 3.333 ± 5.774 (Figure 7), which was sig-
nificantly different from the prevention generated by Maitake Pro4X (64.286 ± 23.862, p < 0.01).
3.1.2. Effect of Maitake D-Fraction Pro4X in the tumor grows that escape to treatment
After analyzing the percentage of prevention in each treatment, now is important to study how 
the tumor grows in the animals that did not respond to the Maitake treatment and escapes its 
control. From Figure 6, 3 of 10 animals escaped the Maitake Pro4X prevention and developed 
breast tumors. We observed that breast tumor in the control group grew linearly 10–24 days 
Figure 6. Effect of Maitake D-Fraction on breast cancer prevention in BALBc mice.
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after tumor challenge; however, in the Maitake group, the breast tumor grew slowly at the 
same time and at 24 days achieved a similar size to compare the untreated  control. At 46 days 
after Tumorigenesis (the end of experiment), the tumor area (cm2) did not achieve a significant 
difference between the groups. The microscopy study of tissue paraffin sections shows that 
the untreated tumors from the control group were solid and have irregular edges; however, 
we were surprised to observe that tumors from the Maitake Pro4X group were almost the 
same size than the controls but full of liquid, not solid, with net tumor round edges, similar 
to benign tumors.
3.1.3. Effect of Maitake Pro4X on tumor necrosis
From the same experiments, we were interested in analyzing the necrosis area in the breast 
tumors. Figure 8 shows the macroscopic aspect of a representative breast tumor at control 
and Maitake groups at the end of the experiment. After measuring the necrosis area (cm) from 
breast tumor in each animal group, it can be concluded that Maitake Pro4X reduce signifi-
cantly (*p < 0.01) the area of necrosis in the surface of the breast tumors that escape to its con-
trol compared to the untreated group. Maitake D-Fraction Pro4X practically did not develop 
necrosis in their tumors (Figure 8).
3.1.4. Effect of Maitake Pro4X on metastasis in liver and lung tissues
The next question that we made is can Maitake Pro4X avoid the metastasis event in those 
animals with breast tumors. In order to verify that, lung and liver tissues were isolated from 
each tumor-bearing mice treated with or without Maitake Pro4X. Weight, macroscopic aspect, 
and sizes of lung and liver from those mice with breast tumors were checked. The lung and 
Figure 7. Percentage of breast cancer prevention induced by Maitake D-Fraction Pro4X in BALBc mice.
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liver tissues’ average area (cm2) from each experimental group were analyzed. No significant 
differences in the size of the lung or the liver tissues from those animals in each experimen-
tal group were found. But nevertheless, macroscopically, liver tissues from the control group 
were completely different, colorless, and rigid, compared to those treated with Maitake Pro4X 
(Figure 9A). The histology of control’s liver tissue shows and confirms cell proliferation and 
hyperplasia. However, liver tissues from Maitake Pro4X treated were darker, similar to nor-
Figure 9. The liver tissues histology (left) of tumor-bearing mice from control (A) and Maitake Pro4X (B). Back arrows 
represent the cell proliferation area. Right pictures from each histology represent the liver tissue in each condition. Red 
arrows represent the metastasis area.
Figure 8. Maitake Pro4X treatment reduces tumor necrosis. The figure represents the pictures of breast tumors isolated 
(left) and in vivo (right) in both groups.
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mal, with normal texture and aspect (Figure 9B). The histology studies from control’s liver tis-
sues indicated the presence of bigger blood vessels, with liver structure different than normal 
and some mitotic changes. Those experiments suggest that the treatment with Maitake Pro4X 
prevent the liver metastasis development.
The macroscopic study of the lung tissues revealed no morphological differences between 
tumor-bearing and nontumor-bearing mice. However, surprisingly, were observed higher 
mitosis percentage in the lung histology sections from control animals (7.50 ± 0.7) compared 
to Maitake Pro4x treatment (0.1 ± 0.02, p < 0.001 in the Pro4X). The percentage of mitosis found 
in the lung tissues pretreated with Maitake pro4X revealed no differences compared to nor-
mal lung tissue.
3.2. Comparison in Breast Tumorigenesis preventive potential: Maitake D-Fraction vs. 
Tamoxifen in experimental biomodel
In order to study whether Maitake D-Fraction can be adjuvant in breast cancer prevention 
with tamoxifen, we employed 20 BALBc female mice, 6–8 weeks old, separated into differ-
ent groups: control group, D-Fraction group, tamoxifen group, and D-Fraction + tamoxifen 
group. The animals were inbred and kept in the Bioterio from BIOMED-UCA in compliance 
with National and International Standards of handling of laboratory animals with adminis-
tration of water and food ad libitum kept on a 12-hour light/12-hour dark at room tempera-
ture, 22°C. Before performing the experiments, we got the approval of the ethical committee 
CICUAE from our Institution BIOMED-UCA for the animal use and manipulation in this 
study. Tumor induction in female mice was performed by exogenous implant of 2 × 105 murine 
tumor LM3 cells. To study the preventive effects of D-Fraction in mammary  tumorigenesis, 
we have been working with 20 BALBc female mice divided in the following groups: control 
group treated orally with the dissolution vehicle; Maitake-treated group, with daily adminis-
tration of 5 mg of β-glucans/kg; tamoxifen-treated group, daily treated with 20 mg of tamoxi-
fen; and combined treatment of tamoxifen and D-Fraction at the indicated doses (tamoxifen 
+ D-Fraction group). The treatments continued for 50 days (equivalent to 5 years in human), 
after that, mammary tumorigenesis were induced. The animals were observed until day 27 
post tumorigenesis (sacrifice day). In this experiment, we observed that Maitake D-Fraction 
protects mammary tissue against tumor development in about 40% (*p < 0.05) (Figure 10 
shows D-Fraction induce tumorigenesis in about 60%); however, we observed that tamoxi-
fen treatment alone prevent only in about 25% (n.s., p-value not significant) against breast 
carcinogenesis. Surprisingly, the coadministration with tamoxifen + D-Fraction prevented 
mammary tumorigenesis in about 80% (**p < 0.01) (Figure 10 shows that combined treatment 
developed only 20% of tumorigenesis). To note, we observed that 100% of control animals 
developed breast tumor (Figure 10).
As for the post-tumorigenesis mortality, 20% of the animals treated with tamoxifen and 25% 
of control animals died after the tumor induction. Surprisingly, there was no mortality in 
Maitake and tamoxifen + Fraction D groups, 100% of the animals surviving at the end of the 
experiment. Figure 11 show the overall survival rate of the animal from each condition at the 
end of the treatment.
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Regarding adverse effects, tamoxifen-treated animals exhibit a remarkable intestinal jaundice, 
less evident in subjects treated with tamoxifen + Maitake, which was absent in the animals 
treated only with Maitake. All the treated groups showed significant increase in serum creati-
nine with p < 0.05 compared to control. These results suggest that D-Fraction has a higher pre-
ventive potential, compared with tamoxifen, in the development of mammary tumorigenesis. 
Figure 11. Overall survival rate after treatment with and without Maitake and tamoxifen alone or in combination.
Figure 10. Breast tumorigenesis induced by Maitake or tamoxifen alone or in combination. Maitake D-Fraction was used 
in a concentration of 5 mg/kg and tamoxifen in concentration of 20 mg/animal. Treatment was performed during 50 days 
in female BALBc mice.
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Moreover, Maitake induce less or no side effects and the maximum overall survival rate in the 
mice. However, we observed from these experiments that tamoxifen and Maitake D-Fraction 
are able to achieve the maximal potential in breast cancer prevention when administered in 
combination.
4. Angiogenesis reduction
We estimate the angiogenic index in the tumoral breast tissues in order to establish if Maitake 
D-Fraction extracts are able to reduce or avoid the tumoral angiogenesis. Figure 12A shows 
the average blood vessels density in each group. Figure 12B shows the microscopy images 
(25×) of those breast tumors from both groups. We observe that the number of blood ves-
sels/mm2 in control’s breast tumor tissues were significantly higher (0.637 ± 0.182, p < 0.05) 
than breast tumors treated with Maitake Pro4X (0.031 ± 0.028). We can also observe from the 
microscopy pictures that the area of control blood vessels are bigger compared to those in the 
breast tissue treated with Maitake Pro4x (Figure 12B).
Figure 12. (A) The graphics of average of blood vessels density/mm2 in each group. (B) The microscopy pictures (25×) of 
breast tumors analyzed. Black arrows indicated the size of blood vessels in each condition. **p<0.01.
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5. Survival increase
5.1. Effect of Maitake extract in the relative survival in BALBc mice
Another aspect in which we were interested was the overall survival of mice at the end of 
the experiment. Figure 13 shows the percentage of overall relative survival at 46 days after 
tumorigenesis initiation when the experiment was terminated and the animals were sacrificed 
to analyze the results. Higher number of animals treated with Maitake D-Fraction lived until 
the end of the experiment. The overall survival in animals from Maitake Pro4X group at the 
end was 50% compared to control that was reduced to 10% (Figure 13). Here, we also ana-
lyzed other Maitake D-Fraction product called Maitake Standard with similar composition 
of Maitake Pro4X, but less concentrated. Both the Maitake compounds did induce a higher 
overall survival in BALBc mice at 46 days after tumorigenesis.
6. Effect of maitake pro4x on specific gene expression related to tumoral 
phenotype inhibition
With the objective to determine if Maitake D-Fraction PRO4X modifies the genomic expres-
sion of tumoral phenotype we isolated total RNA from tumor of all the experimental groups 
and mammary gland of nontumor-bearing mice. We choose genes such as ABCG2, CUL3, 
IGFBP5, PTEN, and SPACR, whose expressions were modified after Maitake treatment in 
MCF-7 cells previously published [25]. For this purpose, total RNA were isolated and after 
purification RT-PCR were performed in each breast tumor tissue from control, Maitake 
Standard, and Maitake Pro4X groups. We also isolated total RNA from normal breast tissue 
treated with Maitake Pro4X resistant to tumorigenesis. In Figure 14A, we shown the gene 
Figure 13. Kaplan-Meier overall survival curves. The graphic represents of overall relative survival from 7 to 50 days 
after tumorigenesis initiation. A green line represents the control group, a blue line represents the Maitake Standard 
treatment, and a red line indicates the survival after Maitake Pro4X treatment. *p<0.05; **p<0.01.
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expression in all the conditions assayed. We observed from this figure that SPARC gene is dif-
ferentially expressed in all the conditions. SPARC gene expression were upmodulated in the 
breast tumor tissues treated with Maitake Pro4X (mouse 2 and mouse 3). On the other hand, 
we observed a downmodulation in the SPACR gene expression corresponding to mouse 4 
treated with Maitake Pro4X. We did not observed PCR amplification of SPARC gene in the 
breast normal tissue without tumor corresponding to a mouse treated with Maitake Pro4X, 
who was resistant to carcinogenesis. We observed a similar pattern in mouse 2 treated with 
Maitake Standard. With respect to the gene expression of PTEN, in Figure 14B, we observed 
that are also differentially expressed in the assayed conditions. In the breast tissues of mouse 
1 and mouse 4 treated with Maitake Pro4X we observed a downmodulation of this gene; 
however, we did not observe expression band in the mouse 2 treated with Maitake Standard 
or in the breast normal tissue resistant to carcinogenesis treated with Maitake Pro4X. ABCGs 
gene are also expressed differentially in all the conditions. No bands were observed in the 
tumoral tissue from mouse 2 treated neither with Maitake Standard, nor in the breast normal 
tissue resistant to carcinogenesis treated with Maitake Pro4X (Figure 14). Moreover, CUL3 
and IGFBP5 genes were expressed in all conditions (Figure 14A). In order to see if there are 
differences in the level of expression we did quantify the PCR reaction with respect to β-actin 
amplifying all genes at 10, 20, 35, and 40 cycles. Figure 14B shows the quantification of each 
PCR reaction.
7. Toxicity studies
7.1.  Acute Toxicity Studies in BALBc mice as biomodel
To investigate if Maitake D-Fraction Pro4X did not generate acute toxicity, we worked with a 
really high concentration of Maitake (2000 mg/kg). For this purpose, we employed 10 female 
Figure 14. Gene expression analysis. (A) The gene expression at mRNA level in all the conditions. (B) Relative 
quantification of each RT-PCR reaction. *p<0.05 and **p<0.01.
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and male BALBc mice, 6–8 weeks old. Control group animals received a single oral dose of 
514 μl of BD (bi-distilled water) and the treat group animals received one oral dose of 514 
μl of D-Fraction (corresponding to 2000 mg/kg of D-Fraction, dose equivalent at approx. 
120 times highest compared with the therapeutic dose employed in previous experiments). 
The animals were observed daily until day 14 after treatment (day of sacrifice). The results 
show a significant increase in the body weight of the male mice from the control group (24.5 
± 1.49 gs) with respect to males treated with Maitake (22.57 ± 2.19 gs), p < 0.05 (Figure 15). 
No significant differences were observed in the body weight of female BALBc mice from 
both groups. We also observed that the Maitake acute treatment reduce significantly the 
value of hematocrite percentage from 33.00 ± 1.22 to 28.20 ± 4.44, with p < 0.05 in the control 
group. The percent of hemoglobin were also significantly reduced from 11.18 ± 0.41% to 9.52 
± 1.53%, with p < 0.05 in the control group. Toxicity tests revealed that the administration of 
a single dose of 2000 mg/kg D-Fraction does not cause mortality or any signs of toxicity in 
any subject. All the individuals survived treatment. Macroscopic examination and histologi-
cal studies confirmed that breast, liver, lung, and kidney tissues from animals treated with a 
single dose of 2000 mg/kg of D-Fraction did not reveal histological alterations or significant 
differences in any tissue compared to controls. We need to study if the slight anemia induced 
by acute dose of Maitake D-Fraction is due to the reduction of Fe-absorption in duodenum.
7.2. Sub-Acute Toxicity Studies in biomodels mice BALBc
To determine whether the subacute dose of Maitake D-Fraction induce toxicity in BALBc 
mice, we worked with 10 female and male mice, 6–8 weeks old, divided into two groups: 
control group that received a daily volume of BD water and treated group daily treated 
orally with 5 mg/kg of D-Fraction during 28 days, after that they were proceeded to sacrifice. 
Toxicity tests revealed that the treatment for 28 days with 5 mg/kg of D-Fraction does not 
cause mortality or any signs of toxicity in any animal. All the individuals survived treat-
Figure 15. Body weight (grams) of male BALBc mice after treatment in the acute dose of Maitake D-Fraction.
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ment. Macroscopic examination and histological studies confirmed that breast, liver, lung, 
and kidney tissues from animals treated for 28 days with 5 mg/kg of D-Fraction did not reveal 
histological alterations or significant differences in any tissue compared to controls.
8. Conclusions
Our results demonstrate that Maitake D-Fraction Pro4X prevents mammary tumorigenesis 
and also increased the overall survival and reduced tumor angiogenesis in BALBc mice. 
It also protects from the adverse effects of chemotherapy and reduces the toxicity of tamoxi-
fen. The LD50 value is above 2000 mg/kg of D-Fraction, proving to be a nontoxic and safe nat-
ural compound for the treatment of animals. It has selective cytotoxicity, causing significant 
cell deaths in tumor cells without affecting normal cells. Although still we needs to determine 
which is the active molecule from the Maitake Pro4X extract and which is the exact molecular 
mechanism utilized to acts as tumor preventive agent. Based upon these results we can pos-
tulate that Maitake D-Fraction Pro4X is a good candidate to be used as a preventive agent in 
breast carcinogenesis in a high-risk population.
All these results suggest that D-Fraction could be applied to the therapy of cancer patients 
under chemotherapy treatment or as preventive agent in individuals with family history and/
or carriers of mutations in BRCA 1 or BRCA2 genes. The beneficial effects of Grifola frondosa 
extract demonstrated in this work could be useful in the near future to reduce the side effects 
of conventional chemotherapy or to use as a preventive agent against mammary tumorigen-
esis in high-risk Argentine population.
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